Related Experiment Videos

Regulation of HDM2 activity by the ribosomal protein L11

Marion A E Lohrum1, Robert L Ludwig, Michael H G Kubbutat

  • 1Regulation of Cell Growth Laboratory, NCI-FRCDC, Frederick, MD 21702, USA.

Cancer Cell
|July 5, 2003
PubMed

Insights

Ribosomal protein L11 stabilizes the p53 tumor suppressor by inhibiting HDM2. This discovery reveals a new pathway for p53 activation linked to ribosome biogenesis, crucial for cancer research.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Cellular Regulation

Background:

  • The HDM2 protein is a key regulator of the p53 tumor suppressor protein's stability and function.
  • Understanding p53 regulation is critical for developing cancer therapies.

Purpose of the Study:

  • To investigate the interaction between ribosomal protein L11 and HDM2.
  • To elucidate the role of this interaction in p53 stabilization and activation.

Main Methods:

  • Co-immunoprecipitation assays to detect protein interactions.
  • Cell-based assays to assess p53 stabilization and activation.
  • Treatment with actinomycin-D to induce perturbations in ribosome biogenesis.

Main Results:

  • Ribosomal protein L11 directly interacts with HDM2, inhibiting its function.
  • L11 binding leads to the stabilization and activation of p53.
  • The HDM2/L11 interaction is enhanced upon treatment with low-dose actinomycin-D, suggesting a role in ribosome biogenesis stress response.

Conclusions:

  • Ribosomal protein L11 represents a novel mechanism for p53 stabilization.
  • The HDM2/L11 pathway offers a new target for modulating p53 activity in cancer.
  • This interaction highlights a link between ribosome biogenesis and tumor suppression.

Related Concept Videos